Towa Pharmaceutical Co Ltd
TSE:4553
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Towa Pharmaceutical Co Ltd
TSE:4553
|
JP |
|
Finolex Industries Ltd
NSE:FINPIPE
|
IN |
|
N
|
Ningbo Boway Alloy Material Co Ltd
SSE:601137
|
CN |
|
BLIS Technologies Ltd
NZX:BLT
|
NZ |
|
Subaru Co Ltd
TSE:9778
|
JP |
|
Granite Construction Inc
NYSE:GVA
|
US |
|
Quanex Building Products Corp
NYSE:NX
|
US |
|
F
|
FGI Industries Ltd
NASDAQ:FGI
|
US |
Wall Street
Price Targets
Price Targets Summary
Towa Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for
Towa Pharmaceutical Co Ltd
is 4 773.6 JPY
with a low forecast of 3 939 JPY and a high forecast of 5 670 JPY.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Towa Pharmaceutical Co Ltd's stock price target?
Price Target
4 773.6
JPY
According to Wall Street analysts, the average 1-year price target for
Towa Pharmaceutical Co Ltd
is 4 773.6 JPY
with a low forecast of 3 939 JPY and a high forecast of 5 670 JPY.
What is Towa Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
6%
For the last 13 years the
compound annual growth rate for
Towa Pharmaceutical Co Ltd's revenue is
14%.
The projected
CAGR
for the next 3 years is
6%.
What is Towa Pharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
-7%
For the last 13 years the
compound annual growth rate for
Towa Pharmaceutical Co Ltd's operating income is
7%.
The projected
CAGR
for the next 13 years is
-7%.
What is Towa Pharmaceutical Co Ltd's Net Income forecast?
Projected CAGR
6%
For the last 13 years the
compound annual growth rate for
Towa Pharmaceutical Co Ltd's net income is
10%.
The projected
CAGR
for the next 3 years is
6%.
